Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd ADR (NY: CANF )

1.970 +0.000 (+0.01%)
Streaming Delayed Price Updated: 11:23 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
Via Benzinga
Can Fite Biofarma: Q1 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Smoking Pot Makes You 55% Less Likely To Develop This Deadly Cancer
Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study  
Via Benzinga
Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results
Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over... 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. 
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
Aspen Aerogels And 28 Stocks Moving Premarket
Gainers 
Via Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1... 
Via Benzinga
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Granted Key NASH Patent in Israel
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced 
Via Benzinga
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.